Difference between revisions of "Team:UCSC/Acetaminophen"
Evan pepper (Talk | contribs) |
Evan pepper (Talk | contribs) |
||
| (92 intermediate revisions by 3 users not shown) | |||
| Line 8: | Line 8: | ||
margin: auto; | margin: auto; | ||
background: honeydew; | background: honeydew; | ||
| − | width: | + | width: 100%; |
} | } | ||
h1 { | h1 { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'!important; |
| − | font-size: | + | font-size: 300%; /*!important*/ |
| + | font-weight: 300 !important; | ||
| + | width: 90%; | ||
| + | } | ||
| + | |||
| + | h2 { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 200%; | ||
| + | font-weight: 300; | ||
| + | } | ||
| + | |||
| + | h3 { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 120%; | ||
| + | font-weight: 400 !important; | ||
} | } | ||
| Line 22: | Line 36: | ||
.proj-button { | .proj-button { | ||
position: relative; | position: relative; | ||
| − | width: | + | width: 25%; |
| + | text-decoration: none !important; | ||
} | } | ||
| Line 28: | Line 43: | ||
opacity: 1; | opacity: 1; | ||
display: inline-block; | display: inline-block; | ||
| − | width: | + | width: 30%; |
| + | height: auto; | ||
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
| + | |||
| + | .proj-button-image-solo { | ||
| + | opacity: 1; | ||
| + | display: inline-block; | ||
| + | width: 65%; | ||
height: auto; | height: auto; | ||
transition: .5s ease; | transition: .5s ease; | ||
| Line 43: | Line 67: | ||
transform: translate(-50%, -50%); | transform: translate(-50%, -50%); | ||
-ms-transform: translate(-50%, -50%) | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: transparent; | ||
| + | color: black; | ||
| + | font-size: 20px; | ||
| + | font-family: "Objektiv-mk1" !important; | ||
| + | font-weight: 400 !important; | ||
| + | padding: 16px 32px; | ||
} | } | ||
.proj-button:hover .proj-button-image { | .proj-button:hover .proj-button-image { | ||
| − | opacity: 0. | + | opacity: 0.2; |
| + | } | ||
| + | |||
| + | .proj-button:hover .proj-button-image-solo { | ||
| + | opacity: 0.2; | ||
} | } | ||
.proj-button:hover .proj-button-desc { | .proj-button:hover .proj-button-desc { | ||
| − | opacity: 0. | + | opacity: 0.8; |
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: transparent; | ||
| + | color: black; | ||
| + | font-size: 20px; | ||
| + | font-family: "Objektiv-mk1" !important; | ||
| + | font-weight: 400 !important; | ||
| + | padding: 16px 32px; | ||
} | } | ||
| Line 61: | Line 107: | ||
.paragraph-left { | .paragraph-left { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 18px; | font-size: 18px; | ||
text-align: left; | text-align: left; | ||
| Line 68: | Line 114: | ||
p { | p { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
/* margin-left: 200px !important; | /* margin-left: 200px !important; | ||
margin-right: 200px !important;*/ | margin-right: 200px !important;*/ | ||
| Line 75: | Line 121: | ||
.firstword { | .firstword { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
| − | font-size: | + | font-size: 65px; |
} | } | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
| − | font-size: | + | font-size: 28px; |
| + | line-height: 130%; | ||
} | } | ||
.quote-person { | .quote-person { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
| − | font-size: | + | font-size: 22px; |
width: 100% !important; | width: 100% !important; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 93: | Line 140: | ||
.titleimg { | .titleimg { | ||
| − | + | vertical-align: middle; | |
| + | width: 25%; | ||
} | } | ||
| Line 101: | Line 149: | ||
.reference-list { | .reference-list { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-size: 12px; | font-size: 12px; | ||
text-align: left; | text-align: left; | ||
| Line 110: | Line 158: | ||
.reference-italic { | .reference-italic { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-size: 12px; | font-size: 12px; | ||
font-style: italic; | font-style: italic; | ||
| Line 116: | Line 164: | ||
figcaption { | figcaption { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-style: italic; | font-style: italic; | ||
font-size: 13px; | font-size: 13px; | ||
| Line 124: | Line 172: | ||
@media (min-width: 1144px) { | @media (min-width: 1144px) { | ||
.container { | .container { | ||
| − | + | width: 100% !important; | |
| − | + | } | |
| − | + | ||
| − | + | .text-container { | |
| − | + | width: 70%; | |
| − | + | padding-left: 15px; | |
| − | + | padding-right: 15px; | |
| − | + | } | |
| − | + | ||
| − | + | .titlebox { | |
| − | + | width: 80%; | |
| − | + | } | |
| − | + | ||
| + | figcaption { | ||
| + | font-size: 16px; | ||
| + | } | ||
} | } | ||
| Line 146: | Line 197: | ||
p { | p { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
margin-left: 10px !important; | margin-left: 10px !important; | ||
margin-right: 10px !important; | margin-right: 10px !important; | ||
| Line 153: | Line 204: | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
| − | font-size: | + | font-size: 26px; |
} | } | ||
.quote-person { | .quote-person { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
| − | font-size: | + | font-size: 20px; |
width: 100%; | width: 100%; | ||
text-align: right; | text-align: right; | ||
| Line 189: | Line 240: | ||
} | } | ||
| − | @media (max-width: | + | @media (max-width: 992px) { |
| − | .proj-button-image { | + | .proj-button-image-solo { |
opacity: 1; | opacity: 1; | ||
display: inline-block; | display: inline-block; | ||
| − | width: | + | width: 30%; |
height: auto; | height: auto; | ||
transition: .5s ease; | transition: .5s ease; | ||
backface-visibility: hidden; | backface-visibility: hidden; | ||
} | } | ||
| + | } | ||
| − | + | @media (max-width: 768px) { | |
| − | + | .proj-button-image { | |
| − | + | opacity: 1; | |
| − | + | display: inline-block; | |
| − | + | width: 32%; | |
| − | + | height: auto; | |
| − | + | transition: .5s ease; | |
| − | + | backface-visibility: hidden; | |
| + | } | ||
| + | |||
| + | .proj-button-image-solo { | ||
| + | opacity: 1; | ||
| + | display: inline-block; | ||
| + | width: 35%; | ||
| + | height: auto; | ||
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
| + | |||
| + | .proj-button-desc { | ||
| + | transition: .5s ease; | ||
| + | opacity: 1; | ||
| + | position: absolute; | ||
| + | top: 100%; | ||
| + | left: 50%; | ||
| + | transform: translate(-50%, -50%); | ||
| + | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: rgba(94, 94, 94, 0.4); | ||
| + | border-radius: 60px; | ||
| + | color: white; | ||
} | } | ||
h1 { | h1 { | ||
| − | + | font-family: 'objektiv-mk1'; /*!important*/ | |
| − | + | font-size: 220%; /*!important*/ | |
| − | + | width: 80%; | |
| + | } | ||
| − | + | h2 { | |
| − | + | font-family: 'objektiv-mk1'; /*!important*/ | |
| − | + | font-size: 20px; /*!important*/ | |
| − | + | } | |
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 20px; | font-size: 20px; | ||
| Line 227: | Line 305: | ||
.quote-person { | .quote-person { | ||
width: 100%; | width: 100%; | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 16px; | font-size: 16px; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 240: | Line 318: | ||
figcaption { | figcaption { | ||
| − | font-size: | + | font-size: 14px; |
| − | line-height: | + | line-height: 140%; |
| + | } | ||
| + | |||
| + | .reference-list { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | text-align: left; | ||
| + | list-style-type: none; | ||
| + | line-height: 100%; | ||
| + | margin-bottom: 80px; | ||
| + | margin-right: -70px; | ||
| + | margin-left: -70px; | ||
} | } | ||
} | } | ||
| Line 252: | Line 341: | ||
@media (max-width: 576px) { | @media (max-width: 576px) { | ||
.proj-button-image { | .proj-button-image { | ||
| − | + | opacity: 1; | |
| − | + | display: inline-block; | |
| − | + | width: 50%; | |
| − | + | height: auto; | |
| − | + | transition: .5s ease; | |
| − | + | backface-visibility: hidden; | |
| − | + | } | |
| − | + | .proj-button-image-solo { | |
| − | + | opacity: 1; | |
| − | + | display: inline-block; | |
| − | + | width: 50%; | |
| − | + | height: auto; | |
| − | + | transition: .5s ease; | |
| − | + | backface-visibility: hidden; | |
| − | + | } | |
| + | |||
| + | .proj-button-desc { | ||
| + | transition: .5s ease; | ||
| + | opacity: 1; | ||
| + | position: absolute; | ||
| + | top: 100%; | ||
| + | left: 50%; | ||
| + | transform: translate(-50%, -50%); | ||
| + | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: rgba(94, 94, 94, 0.5); | ||
| + | border-radius: 60px; | ||
| + | color: white; | ||
| + | font-size: 12px; | ||
} | } | ||
.firstword { | .firstword { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 70px; | font-size: 70px; | ||
} | } | ||
| − | + | .titleimg { | |
| − | + | vertical-align: middle; | |
| − | + | width: 40%; | |
| − | + | } | |
| − | + | ||
p { | p { | ||
| − | + | font-family: 'objektiv-mk1' !important; | |
| − | + | margin-left: 10px !important; | |
| − | + | margin-right: 10px !important; | |
| − | + | font-size: small !important; | |
| − | + | } | |
h1 { | h1 { | ||
| − | + | font-size: 140%; | |
| − | + | } | |
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 17px; | font-size: 17px; | ||
| Line 300: | Line 404: | ||
.quote-person { | .quote-person { | ||
width: 60% !important; | width: 60% !important; | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 12px; | font-size: 12px; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 308: | Line 412: | ||
.paragraph-left { | .paragraph-left { | ||
font-size: 13px; | font-size: 13px; | ||
| − | line-height: | + | line-height: 170%; |
} | } | ||
| Line 315: | Line 419: | ||
padding-left: 0px; | padding-left: 0px; | ||
padding-right: 0px; | padding-right: 0px; | ||
| + | } | ||
| + | |||
| + | .metabolic-pathway { | ||
| + | margin: auto; | ||
| + | background: honeydew; | ||
| + | width: 110%; | ||
| + | margin-left: -20px; | ||
| + | margin-right: -20px; | ||
} | } | ||
figcaption { | figcaption { | ||
| − | font-size: | + | font-size: 12px; |
| − | line-height: | + | line-height: 130%; |
| + | } | ||
| + | |||
| + | .reference-list { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | text-align: left; | ||
| + | list-style-type: none; | ||
| + | line-height: 100%; | ||
| + | margin-bottom: 80px; | ||
| + | margin-right: -50px; | ||
| + | margin-left: -50px; | ||
} | } | ||
} | } | ||
| Line 335: | Line 458: | ||
<div id="page"> | <div id="page"> | ||
<center> | <center> | ||
| − | + | <br> | |
| + | <br> | ||
| − | + | <img class="titleimg" src="https://static.igem.org/mediawiki/2017/c/cf/Acetaminophen.png"> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| + | <h1>ACETAMINOPHEN METABOLICS</h1> | ||
| + | |||
| + | <br> | ||
| + | |||
| + | <div class="text-container"> | ||
<div class="container"> | <div class="container"> | ||
<p><span class="quote">"Antipyretic drugs, by being analgesics, reduce not only the fever but also the pain."</span></p> | <p><span class="quote">"Antipyretic drugs, by being analgesics, reduce not only the fever but also the pain."</span></p> | ||
| Line 357: | Line 477: | ||
<br> | <br> | ||
| − | <div class="metabolic-pathway"> | + | <!-- <div class="container"> --> |
| − | + | <div class="metabolic-pathway"> | |
| − | </div> | + | <img src="https://static.igem.org/mediawiki/2017/c/ca/Acet-syn.png" style="width: 100%;"> |
| + | </div> | ||
| + | <!-- </div> --> | ||
| + | <br> | ||
<br> | <br> | ||
<br> | <br> | ||
| − | <div class="text-container"> | + | <!-- <div class="text-container"> --> |
| − | <div class="paragraph-left"> | + | <!-- <div class="paragraph-left"> --> |
| − | + | <p>We aim to genetically modify <i>S. elongatus</i> PCC 7942 to produce acetaminophen, a common mild anesthetic and antipyretic recognized by the WHO as an essential medicine<sup>[1]</sup>. However, in many countries with lower regulations and faulty policies regarding drug manufacturing, acetaminophen can be synthesized with lethal toxins that result in hundreds of deaths worldwide<sup>[23]</sup>. Acetaminophen is often used in conjunction with opioid pain medications postoperatively to enhance pain relief, thus reducing reliance upon opioid pharmaceuticals<sup>[24]</sup>.</p> | |
| − | </div> | + | <!-- </div> --> |
| − | </div> | + | <!-- </div> --> |
<!-- <div class="container"> | <!-- <div class="container"> | ||
| Line 374: | Line 497: | ||
<div class="col-md-8"> | <div class="col-md-8"> | ||
<figure> | <figure> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/4/4d/Acetaminophensyn.png" style="width: 100%;"> |
| − | <figcaption style="font-family: ' | + | <figcaption style="font-family: 'objektiv-mk1'; font-style: italic; font-size: 13px;">Current synthetic biology approach to manufacturing acetaminophen in E.coli <sup>[25, 26]</sup>.Genes 4ABH and nhoA were inserted to synthesize the pathway in PCC 7942. The gene from A.bisporus, 4ABH, produces 4-aminophenol while the E. coli gene nhoA converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> |
</figure> | </figure> | ||
</div> | </div> | ||
| Line 386: | Line 509: | ||
</div> --> | </div> --> | ||
| − | <div class=" | + | <div class="metabolic-pathway"> |
| − | <div class="row"> | + | <!-- <div class="row"> --> |
<figure> | <figure> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/4/4d/Acetaminophensyn.png" style="width: 100%; padding: 20px"> |
<figcaption>Current synthetic biology approach to manufacturing acetaminophen in <span style="font-style: italic";>E. coli</span> <sup>[25, 26]</sup>. Genes <span style="font-style: italic";>4ABH</span> and <span style="font-style: italic";>nhoA</span> were inserted to synthesize the pathway in PCC 7942. The gene from <span style="font-style: italic";>A. bisporus, 4ABH</span>, produces 4-aminophenol while the <span style="font-style: italic";>E. coli</span> gene <span style="font-style: italic";>nhoA</span> converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> | <figcaption>Current synthetic biology approach to manufacturing acetaminophen in <span style="font-style: italic";>E. coli</span> <sup>[25, 26]</sup>. Genes <span style="font-style: italic";>4ABH</span> and <span style="font-style: italic";>nhoA</span> were inserted to synthesize the pathway in PCC 7942. The gene from <span style="font-style: italic";>A. bisporus, 4ABH</span>, produces 4-aminophenol while the <span style="font-style: italic";>E. coli</span> gene <span style="font-style: italic";>nhoA</span> converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> | ||
</figure> | </figure> | ||
| − | </div> | + | <!-- </div> --> |
</div> | </div> | ||
| Line 399: | Line 522: | ||
<br> | <br> | ||
<br> | <br> | ||
| − | <div class="text-container"> | + | <!-- <div class="text-container"> |
| − | <div class="paragraph-left"> | + | <div class="paragraph-left"> --> |
| − | + | <p>We are using a previously engineered pathway in <span style="font-style: italic";>E. coli</span> as a model of acetaminophen biosynthesis to enhance PCC 7942<sup>[26, 25]</sup>. The pathway converts chorismate, an abundant amino acid precursor of tryptophan, phenylalanine, and tyrosine, into acetaminophen with the addition ofthe <span style="font-style: italic";>4ABH</span> gene from <span style="font-style: italic";>A. bisporus</span>, an edible mushroom, and <span style="font-style: italic";>nhoA</span> from <span style="font-style: italic";>E. coli</span>. For more information on acetaminophen metabolics, check out <a href="https://2017.igem.org/Team:UCSC/Model">our modeling page!</a></p> | |
| − | </div> | + | <!-- </div> |
| − | </div> | + | </div> --> |
<br> | <br> | ||
<br> | <br> | ||
| + | <br> | ||
| + | |||
| + | <div class="container" style="width: 100%"> | ||
| + | <div class="row"> | ||
| + | <div class="col-md-4"> | ||
| + | <h3>P R O J E C T</h3> | ||
| + | <hr> | ||
| + | <a href="https://2017.igem.org/Team:UCSC/Project" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/6/64/UCSCproject.png" class="proj-button-image-solo"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">HOMEPAGE</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | </div> | ||
| + | |||
| + | <div class="col-md-8"> | ||
| + | <h3>Click here to learn more!</h3> | ||
| + | <hr> | ||
| + | <div class="row"> | ||
| + | <a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/a/a2/B12_flask_button.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">VITAMIN B<sub>12</sub></div> | ||
| + | </div> | ||
| + | </a> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Model" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/b/be/Modeling_button.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">MODELING</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Demonstrate" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/a/ad/Resulticon.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">RESULTS</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | </div> | ||
| + | <div class="row"> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Target-Organism" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/8/84/Spirulinaicon.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">TARGET ORGANISM</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Part_Collection" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/9/9c/Parts_icon.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">PARTS</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | </div> | ||
| + | </div> | ||
| + | </div> | ||
<br> | <br> | ||
<div class="container"> | <div class="container"> | ||
<div class="reference-list"> | <div class="reference-list"> | ||
| − | <li>[1] World Health Organization, ed.,<span class="reference-italic">The Selection and Use of Essential Medicines: report of | + | <hr> |
| + | <li>[1] World Health Organization, ed.,<span class="reference-italic">The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2007 ; (including the 15th model list of essential medicines).</span> No. 946in WHO Technical Report Series, Geneva: World Health Organization, 2007. OCLC: 254437808.</li> | ||
<li>[23] P. N. Newton, M. D. Green, and F. M. Fern ́andez, “Impact of poor-quality medicines in the‘developing’ world,”<span class="reference-italic">Trends in Pharmacological Sciences</span>, vol. 31, pp. 99–101, Mar. 2010.</li> | <li>[23] P. N. Newton, M. D. Green, and F. M. Fern ́andez, “Impact of poor-quality medicines in the‘developing’ world,”<span class="reference-italic">Trends in Pharmacological Sciences</span>, vol. 31, pp. 99–101, Mar. 2010.</li> | ||
<li>[24] S. A. Schug, D. A. Sidebotham, M. McGuinnety, J. Thomas, and L. Fox, “Acetaminophen as anadjunct to morphine by patient-controlled analgesia in the management of acute postoperativepain,”<span class="reference-italic">Anesthesia and Analgesia</span>, vol. 87, pp. 368–372, Aug. 1998.</li> | <li>[24] S. A. Schug, D. A. Sidebotham, M. McGuinnety, J. Thomas, and L. Fox, “Acetaminophen as anadjunct to morphine by patient-controlled analgesia in the management of acute postoperativepain,”<span class="reference-italic">Anesthesia and Analgesia</span>, vol. 87, pp. 368–372, Aug. 1998.</li> | ||
| Line 418: | Line 600: | ||
</div> | </div> | ||
</div> | </div> | ||
| + | |||
| + | <br> | ||
| + | <br> | ||
</center> | </center> | ||
</div> | </div> | ||
| + | </center> | ||
</body> | </body> | ||
</html> | </html> | ||
| − | |||
{{UCSC-Footer}} | {{UCSC-Footer}} | ||
Latest revision as of 01:44, 2 November 2017
ACETAMINOPHEN METABOLICS
"Antipyretic drugs, by being analgesics, reduce not only the fever but also the pain."
~Clinical Manual of Fever in Children
We aim to genetically modify S. elongatus PCC 7942 to produce acetaminophen, a common mild anesthetic and antipyretic recognized by the WHO as an essential medicine[1]. However, in many countries with lower regulations and faulty policies regarding drug manufacturing, acetaminophen can be synthesized with lethal toxins that result in hundreds of deaths worldwide[23]. Acetaminophen is often used in conjunction with opioid pain medications postoperatively to enhance pain relief, thus reducing reliance upon opioid pharmaceuticals[24].
We are using a previously engineered pathway in E. coli as a model of acetaminophen biosynthesis to enhance PCC 7942[26, 25]. The pathway converts chorismate, an abundant amino acid precursor of tryptophan, phenylalanine, and tyrosine, into acetaminophen with the addition ofthe 4ABH gene from A. bisporus, an edible mushroom, and nhoA from E. coli. For more information on acetaminophen metabolics, check out our modeling page!
